Nifedipine

IMPORTANT: Nifedipine is available in two distinct formulations with different dosing schedules and indications. Nifedipine 10 mg capsules are immediate-release and are taken three times daily. Nifedipine modified-release tablets (20 mg, 30 mg, 60 mg) are taken once or twice daily depending on the specific product. These formulations are NOT interchangeable. Always check that you have been dispensed the correct formulation and strength as prescribed. If in doubt, ask your pharmacist before taking the medicine.

Nifedipine is one of the most widely used calcium channel blockers in the UK, with a long clinical history in cardiovascular therapy. Nifedipine tablets are available in two formulations: an immediate-release capsule and modified-release tablets. They are used in adults to treat high blood pressure and angina. Because the two formulations have different dosing schedules and are not interchangeable, it is important to take the formulation your prescriber has specified. A prescription can only be issued following a clinical consultation.

Nifedipine is an oral prescription medicine belonging to the dihydropyridine class of calcium channel blockers. It works by blocking calcium channels in blood vessel walls, causing vasodilation and a reduction in blood pressure. Nifedipine is available in the UK in two distinct oral formulations, each with different pharmacokinetic properties and dosing requirements.

Nifedipine 10 mg Immediate-Release Capsules

The 10 mg capsule is an immediate-release formulation. It is absorbed rapidly and has a relatively short duration of action, requiring dosing three times daily. In the UK, the immediate-release capsule is licensed for the treatment of angina and hypertension. However, due to the rapid peak in drug concentration it produces, the immediate-release formulation is associated with a higher incidence of acute side effects such as flushing, headache, and reflex tachycardia compared to modified-release products. The immediate-release capsule should never be chewed, as this dramatically increases the speed of absorption.

Nifedipine Modified-Release Tablets (20 mg, 30 mg, 60 mg)

Modified-release nifedipine tablets contain the same active ingredient but release it slowly over a longer period, maintaining more consistent plasma levels and reducing the peaks and troughs associated with the immediate-release formulation. Depending on the specific product and brand, modified-release nifedipine is taken once or twice daily. Some modified-release products are licensed for hypertension, some for angina, and some for both. Refer to the Patient Information Leaflet supplied with your specific product for the indications and dosing schedule that apply.

Because different modified-release nifedipine products are not necessarily bioequivalent to one another, your prescriber should specify the brand as well as the dose when prescribing modified-release nifedipine. If your pharmacist supplies a different brand, check with your prescriber before taking it.

Nifedipine lowers blood pressure and helps to prevent angina through its action on calcium channels in blood vessel walls.

Calcium Channel Blockade and Vasodilation

In the smooth muscle cells lining blood vessel walls, calcium enters through voltage dependent calcium channels, triggering contraction and narrowing of the vessel. Nifedipine selectively blocks these channels in vascular smooth muscle. By preventing calcium from entering, nifedipine causes the smooth muscle to relax. Blood vessels widen, reducing peripheral vascular resistance and lowering blood pressure.

Benefits for Angina

In angina, the heart does not receive enough oxygen because of narrowed coronary arteries. Nifedipine improves blood flow by relaxing and dilating coronary arteries and reducing the resistance in peripheral blood vessels. The reduced peripheral resistance lowers the workload of the heart, reducing its oxygen demand. These combined effects help to prevent the chest pain episodes associated with chronic stable angina and, in some formulations, Raynaud's syndrome.

Modified-release nifedipine delivers the active ingredient gradually, avoiding the sharp rise and fall in drug levels seen with immediate-release products. This smoother pharmacokinetic profile produces a more sustained and even blood pressure-lowering effect throughout the day, which is associated with better tolerability and consistent cardiovascular protection.

Always take nifedipine exactly as your prescriber instructs. The dosing schedule differs significantly between formulations. Read the Patient Information Leaflet supplied with your specific product before starting treatment.

Immediate-Release Capsules (10 mg)

• Take the capsule three times daily, at approximately the same times each day.
• Swallow the capsule whole. Do not chew or bite into the capsule.
• The capsule can be taken with or without food.

Modified-Release Tablets (20 mg, 30 mg, 60 mg)

• Take once or twice daily as directed by your prescriber and as specified on the Patient Information Leaflet for your specific brand.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet. Doing so destroys the modified-release mechanism.
• Some modified-release nifedipine products should be taken with food. Others can be taken without food. Follow the specific instructions in your product leaflet.

For all formulations:

• Avoid grapefruit and grapefruit juice throughout treatment. Grapefruit can significantly increase nifedipine blood levels, increasing the risk of side effects.
• If you miss a dose, take it as soon as you remember on the same day. If you only remember the following day, skip the missed dose and continue as normal. Do not take two doses at once.
• Do not stop taking nifedipine without speaking to your prescriber first. Stopping angina treatment suddenly may cause a return of symptoms.

Nifedipine is available in four strengths across its two formulation types. The appropriate formulation, strength, and dosing frequency are determined by your prescriber based on the condition being treated and your individual clinical response.

Nifedipine 10 mg (Immediate-Release Capsules)

The 10 mg capsule is an immediate-release formulation taken three times daily. The usual dose for hypertension and angina is 10 mg three times daily, with a maximum of 20 mg three times daily in some patients. Immediate-release nifedipine is generally used less often than modified-release formulations in current clinical practice, partly because of the more pronounced vasodilatory side effects associated with the rapid absorption profile.

Nifedipine 20 mg Modified-Release Tablets

The 20 mg modified-release tablet is typically taken twice daily. It provides an intermediate dose option suitable for patients in whom a lower total daily dose of modified-release nifedipine is appropriate. This strength may be used for angina or hypertension depending on the licensed indications of the specific product supplied.

Nifedipine 30 mg Modified-Release Tablets

The 30 mg modified-release tablet may be taken once or twice daily depending on the product. Once-daily modified-release products at 30 mg provide sustained blood pressure control over 24 hours from a single dose. This strength is within the standard dosing range for hypertension and angina management with modified-release nifedipine.

Nifedipine 60 mg Modified-Release Tablets

The 60 mg modified-release tablet is a higher strength option, typically taken once daily. It is used in patients who require a higher dose for adequate blood pressure or angina control. The maximum daily dose of nifedipine is generally 120 mg, though individual product SmPCs vary. All dose decisions are made by your prescriber. Do not change your dose without medical advice.

Like all medicines, nifedipine can cause side effects. The immediate-release formulation generally produces more acute vasodilatory side effects due to its rapid absorption profile. The information below is based on the current UK SmPC. Refer to the Patient Information Leaflet for the full list of side effects for your specific product.

Common Side Effects (may affect up to 1 in 10 people)

• Headache, particularly at the start of treatment
• Flushing or a feeling of warmth. More pronounced with immediate-release formulations.
• Oedema (swelling of the ankles and lower legs)
• Dizziness or lightheadedness
• Palpitations or a faster than normal heart rate (tachycardia). More common with immediate-release nifedipine due to the rapid fall in blood pressure triggering a reflex heart rate increase.
• Fatigue

Uncommon Side Effects (may affect up to 1 in 100 people)

• Low blood pressure (hypotension)
• Nausea or gastrointestinal discomfort
• Skin rash or itching
• Increased frequency of passing urine

Serious Side Effects: Seek Urgent Medical Attention

Go to your nearest accident and emergency department or call 999 immediately if you experience:

• Worsening chest pain, particularly in the first days of treatment. Calcium channel blockers can occasionally precipitate angina when first introduced. Seek medical advice promptly if this occurs.
• Signs of a severe allergic reaction such as sudden swelling of the face, lips, tongue, or throat, or difficulty breathing
• Severe low blood pressure causing collapse or loss of consciousness

Report any suspected side effect to your prescriber, pharmacist, or via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Nifedipine Tablets May Be Suitable If You:

• Are an adult with a confirmed diagnosis of hypertension or chronic stable angina pectoris
• Require antihypertensive medication or angina relief as part of your cardiovascular therapy
• Are already prescribed nifedipine and require a repeat prescription through an online prescribing service

Nifedipine Tablets Are Not Suitable If You:

• Have unstable angina or are in the acute phase of a heart attack. Immediate-release nifedipine is specifically contraindicated for use in acute coronary syndromes.
• Have significant aortic stenosis
• Have decompensated heart failure
• Are pregnant. Nifedipine should be used in pregnancy only under specialist supervision. The immediate-release capsule is not licensed for routine use in pregnancy. Modified-release nifedipine has a specific licensed use for hypertension in pregnancy under specialist care, but this would not typically be initiated through an online prescribing service.
• Are breastfeeding
• Have a known allergy or hypersensitivity to nifedipine, other dihydropyridines, or any excipient listed in the SmPC
• Are under 18 years of age

Tell your prescriber about all medicines you take. The following interactions are of particular clinical importance for nifedipine:

• Grapefruit and grapefruit juice: grapefruit inhibits the CYP3A4 enzyme responsible for metabolising nifedipine in the gut wall. This significantly increases nifedipine blood levels. Avoid grapefruit entirely throughout treatment.
• CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, clarithromycin, and HIV protease inhibitors: these increase nifedipine levels and may enhance blood pressure lowering and side effects.
• CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, and phenobarbitone: these reduce nifedipine levels and may reduce its effectiveness.
• Beta blockers: combining nifedipine with a beta blocker is clinically common and generally safe. However, the combination should be assessed by a prescriber, as it can occasionally cause excessive blood pressure lowering.
• Digoxin: nifedipine may increase digoxin blood levels. Monitoring of digoxin levels may be required.
• Ciclosporin: nifedipine may increase ciclosporin blood levels. Monitoring is required.
• Quinidine: nifedipine may reduce quinidine blood levels.

Your prescriber will review all current medicines during the clinical assessment before any prescription is considered.

Nifedipine is a Prescription Only Medicine. The clinical consultation is the essential first step. A prescription will only be issued if a registered prescriber concludes, based on their individual assessment of your circumstances, that nifedipine is clinically appropriate for you.

During your online consultation with Pharmacy Planet, a registered prescriber will review the information you provide. This includes your diagnosis, blood pressure history, any relevant cardiac history, current medicines, and other aspects of your medical background. The prescriber will also consider which formulation and strength of nifedipine is appropriate, and confirm the correct dosing schedule. Not all consultations will result in a prescription.

If you are under the care of your GP or a cardiologist for hypertension or angina, please keep them informed of all medicines prescribed through online services. This supports safe and coordinated BP regulation and cardiovascular therapy.

• Store below 25°C.
• Store in the original packaging to protect from light and moisture.
• Keep out of the sight and reach of children.
• Do not use after the expiry date printed on the packaging.
• Do not dispose of medicines via household waste or wastewater. Return unused or out of date medicines to your pharmacist for safe disposal.
• Full storage instructions are provided in the Patient Information Leaflet supplied with your specific nifedipine product.

The table below compares calcium channel blocker tablets. Dihydropyridines (such as amlodipine and nifedipine) act mainly on blood vessels. Non-dihydropyridines (verapamil and diltiazem) also slow the heart rate and have antiarrhythmic properties.

Important: This comparison is for general information only and does not replace medical advice. A prescriber will decide which treatment is suitable for you following an online consultation.

Pharmacy Planet is a GPhC-registered online pharmacy providing access to prescription medicines through a clinically led consultation process. Our registered prescribers and pharmacists are committed to patient safety, clinical accuracy, and responsible prescribing.

We follow GPhC standards, MHRA guidance, and ASA advertising regulations in all aspects of our service. Every prescription is reviewed and dispensed by qualified healthcare professionals. We provide clear, factual information to help patients understand their antihypertensive medication and make informed decisions about their cardiovascular therapy and heart health.

If you have questions about nifedipine or any other medicine, our pharmacy team is available to help. We are committed to transparent, patient centred care.

References

1. Electronic Medicines Compendium (eMC). Nifedipine immediate-release and modified-release products — Summaries of Product Characteristics. https://www.medicines.org.uk/emc. Accessed May 2026.
2. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. https://www.nice.org.uk/guidance/ng136. Accessed May 2026.
3. NHS. High blood pressure (hypertension). https://www.nhs.uk/conditions/high-blood-pressure-hypertension. Accessed May 2026.
4. Joint Formulary Committee. British National Formulary (BNF). Nifedipine. BMJ Group and Pharmaceutical Press. https://bnf.nice.org.uk. Accessed May 2026.
5. Medicines and Healthcare products Regulatory Agency (MHRA). Yellow Card — report a side effect. https://yellowcard.mhra.gov.uk. Accessed May 2026.